Genta Incorporated (Nasdaq: GNTA) today announced that it has acquired world-wide rights from Temple University to intellectual property and technology, and a novel antisense compound (LR3001) that targets c-myb, a central gene that regulates the growth of cancer cells. LR3001 was developed at Temple and has been tested in two Phase 1 clinical trials at the University of Pennsylvania in patients with drug-resistant myeloid leukemia. To date, clinical investigations have been supported by grants from the National Institutes of Health, including the Rapid Access to Investigational Drugs (RAID) program. A request for designation of LR3001 as an Orphan Drug for the treatment of chronic myelocytic leukemia (CML) has been submitted to the U.S. Food and Drug Administration.
"C-myb was one of the first oncogenes to be characterized, and it is believed to play a central role in the growth and differentiation of cancer cells," said Dr. Raymond P. Warrell, Jr., Genta's Chairman and Chief Executive Officer. "Target selection is probably the most critical factor for the success of antisense in specific diseases. The role of c-myb in regulation of early stem cells is well established, and its targeting represents an important new opportunity for our RNA/DNA Medicines Program."
O Clubeinvest.com informa que nenhuma da informação
aqui facultada deverá ser entendida como conselho ou recomendação
de qualquer tipo de transacção ou investimento.
